The United States market has shown robust performance, rising 1.3% over the last week and 28% over the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and scalability potential to capitalize on these favorable conditions.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
AppLovin	21.01%	21.71%	★★★★★★
Sandisk	39.13%	40.96%	★★★★★★
Krystal Biotech	29.09%	36.48%	★★★★★★
Reddit	21.88%	25.36%	★★★★★★
Palantir Technologies	30.22%	31.80%	★★★★★★
Fabrinet	21.38%	23.34%	★★★★★★
Marker Therapeutics	64.28%	69.04%	★★★★★★
Tenaya Therapeutics	59.68%	60.87%	★★★★★☆
KVH Industries	28.67%	146.09%	★★★★★☆
Gorilla Technology Group	54.35%	96.69%	★★★★★☆

Here's a peek at a few of the choices from the screener.

Five9 (FIVN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Five9, Inc. offers intelligent cloud software solutions for contact centers globally and has a market capitalization of approximately $1.74 billion.

Operations: The company generates revenue primarily from its Internet Software & Services segment, totaling approximately $1.17 billion.

With a notable shift in its governance structure and a robust share repurchase program, Five9 is positioning itself for strategic agility and shareholder confidence. Recent earnings have shown a significant uptick, with Q1 sales jumping to $305.32 million from $279.71 million year-over-year, and net income soaring to $18.41 million from just $0.576 million, reflecting operational efficiency and market responsiveness. The company's forward-looking guidance anticipates steady revenue growth with projections ranging up to $1.266 billion for the year, alongside an expected net income of up to $72.47 million, signaling strong future prospects amidst competitive pressures in the tech sector.

Anavex Life Sciences (AVXL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Anavex Life Sciences Corp. is a biopharmaceutical company with a market capitalization of $251.14 million.

Operations: The company focuses on developing therapies for neurodegenerative and neurodevelopmental disorders. As a biopharmaceutical entity, it primarily invests in research and development to advance its pipeline of drug candidates.

Anavex Life Sciences, amidst recent governance reshuffles and compliance challenges with NASDAQ listing requirements, continues to push forward in high-growth sectors like Alzheimer's and Parkinson’s disease treatments. Despite a setback with the European Medicines Agency, their commitment to advancing blarcamesine demonstrates a strategic focus on addressing critical unmet medical needs. The company's R&D dedication is evident from its ongoing trials and regulatory engagements aimed at enhancing therapeutic efficacy through precision medicine strategies. This approach could potentially reshape treatment paradigms in neurodegenerative diseases, reflecting Anavex’s pivotal role in biotechnological innovations within the healthcare sector.

Krystal Biotech (KRYS)

Simply Wall St Growth Rating: ★★★★★★

Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs in the United States, with a market cap of approximately $8.92 billion.

Operations: Krystal Biotech generates revenue primarily from the discovery, development, manufacturing, and commercialization of genetic medicines, amounting to $417.30 million.

Krystal Biotech's recent strides in the biotech sector underscore its robust growth trajectory, highlighted by a 29.1% annual revenue increase and an impressive 36.5% surge in earnings. The firm's strategic R&D investments have catalyzed innovations such as VYJUVEK, the first gene therapy for DEB approved in multiple regions, including the recent UK authorization which promises up to 12 years of market exclusivity. This approval not only enhances Krystal’s product portfolio but also solidifies its position in genetic medicine, leveraging cutting-edge research to address unmet medical needs effectively. With a strong focus on expanding treatment options and a promising financial outlook marked by significant earnings growth and positive free cash flow, Krystal Biotech is poised to make impactful advances in healthcare technology.

Where To Now?

• Investigate our full lineup of 69 US High Growth Tech and AI Stocks right here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.